Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease
Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson's disease (PD). Background: Despite decades of intensive research, to date,…Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital
Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease
Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…PARK-OMM – An osteopathic manipulative medicine protocol to improve motor function and balance in Parkinson’s disease
Objective: To evaluate the effects of a pre-defined Osteopathic Manipulative Medicine (OMM) treatment protocol (PARK-OMM) for 6 weeks compared to a 6-week controlled counseling period…Pathological findings from two Parkinson’s disease patients after intraputaminal GDNF infusion
Objective: To describe the postmortem findings from two patients who underwent intraputaminal infusion of glial-derived neurotrophic factor (GDNF). Background: GDNF has been shown to have…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 207
- Next Page »